Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ).
Shanghai Haohai Biological Technology has established a remuneration and appraisal committee under its board of directors to strengthen its remuneration management system and corporate governance. The committee is composed mainly of independent non-executive directors, with a chairman drawn from among them, and its structure must comply with Chinese company law and the listing rules of both Shanghai and Hong Kong.
The new working rules set out the committee’s mandate to design, supervise and refine performance evaluation indicators and remuneration systems for directors and senior management. It will recommend overall remuneration policies, determine individual pay and termination compensation, and benchmark against comparable companies and group employment conditions to ensure transparency, fairness and alignment with the company’s strategic objectives.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biopharmaceutical and medical technology sector, focusing on the development and commercialization of biological materials and related healthcare products. The company is listed on both the STAR Market of the Shanghai Stock Exchange and The Stock Exchange of Hong Kong, and is subject to corresponding corporate governance and listing regulations.
Average Trading Volume: 156,816
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.46B
For a thorough assessment of 6826 stock, go to TipRanks’ Stock Analysis page.